Skip to main content

Table 1 Demographic, pathophysiological and treatment characterization of SLE patients

From: Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic lupus erythematosus

Parameters

Inactive SLE (SLEDAI ≤ 3)

Active SLE (SLEDAI > 3)

Pvaluea

Total numbers (n)

17

24

N/Ab

Age at study (years)

   

  Median

35

36

0.474

  Range

21-62

25-50

 

Sex (n)

   

  Female

15

22

N/A

  Male

2

2

N/A

Duration of disease (years)

   

  Median

8

8

0.577

  Range

1-22

1-27

 

Clinical parameters (mean ± SD)

   

  White Blood Cells (x109/L)

5.6 ± 1.8

4.9 ± 1.8

0.218

Clinical signs (n)

   

  Muco-cutaneous

11

13

N/A

  Haematological

8

12

N/A

  Neurological/Psychiatric

-

5

N/A

  Serositis

-

6

N/A

  Renal

6

20

N/A

  Joint

12

14

N/A

SLE activity (mean ± SD [range])

   

  SLEDAI score

0.4 ± 0.2 [0-2]

9.1 ± 3.8 [4-18]***

<0.0001

B-cell subsets (mean ± SEM [range], x10 6 /L)

   

  Total CD19+ B cells

554.2 ± 121.9 [54-2077]

319.3 ± 73.9 [6-1303]

0.0585

  CD27- naive B cells

398.6 ± 104.1 [17.9-1757]

217.1 ± 62.1 [0.7-1205]*

0.0403

  Overall CD27+ B cells

146.2 ± 22.7 [35.1-323.2]

96.6 ± 16.8 [5.3-292.8]

0.0585

  CD27+ memory B cells

127.5 ± 20.1 [30.3-273.6]

82.8 ± 15.2 [1.9-279.3]

0.0534

  CD27high plasma B cells

19 ± 3.3 [4.9-49.6]

13.9 ± 2.6 [0.9-44.2]

0.0879

Treatment (n)

   

   None

4

1

N/A

   Prednisolone

5

20

N/A

   Azathioprine

8

19

N/A

   Methotrexate

2

1

N/A

   Hydroxychloroquine

6

7

N/A

   Mycophenolate Mofetil

2

3

N/A

   Cyclophosphamide

-

2

N/A

   Leflunomide

-

1

N/A

  1. aMann-Whitney U-test; bN/Ab: Not Applicable.